Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases.
Insmed stock last closed at $143.50, down 1.24% from the previous day, and has increased 95.76% in one year. It has overperformed other stocks in the Biotechnology industry by 1.48 percentage points. Insmed stock is currently +137.58% from its 52-week low of $60.40, and -2.27% from its 52-week high of $146.84.
As of Sep 3, 2025, there are 182.14M shares of INSM outstanding. The market cap of INSM is $26.14B. In the past 24 hours, 2.5M INSM shares were traded.
You will need a brokerage account to access the NASDAQ market and buy INSM stock.
Based on our experience, eToro is the best brokerage. Here's why:
Get $10 towards your purchase of stock by signing up for an account with eToro today. This offer is only for US users.
Open eToro AccountNow that you've selected the best brokerage, it's time to fill out some personal details so you can buy INSM stock today.
Now that you have filled out your info on the best stock broker app, your next step is to transfer the money for your investment:
Watch the video below for more details transferring funds into your brokerage account.
Once you have identified the best place to buy Insmed stock, it's very important to evaluate their stock prior to buying, so you actually comprehend the risk as well as the upside.
WallStreetZen was created to help average investors perform better fundamental analysis.
You can view all of the due diligence checks on INSM's stock page.
Analysts use a variety of different financial metrics, analyses, models, and charts to gauge INSM's fair value.
Using relative valuations metrics:
You can do more valuation analysis on INSM's stock here.
Out of 15 Equities analysts who give recommendations on INSM, the consensus analyst rating on INSM is a Strong Buy
It's important to note that analyst forecasts are not stock recommendations, nor are they financial advice.
Andrew S. Fein, a top 36% analyst from HC Wainwright & Co. maintains INSM with a buy rating and raises their INSM price target from $120.00 to $240.00, on Aug 13, 2025.
Trung Huynh, a top 11% analyst from UBS maintains INSM with a strong buy rating and raises their INSM price target from $133.00 to $140.00, on Aug 13, 2025.
UBS's Trung Huynh raised their price target on Insmed (NASDAQ: INSM) by 5.3% from $133 to $140 on 2025/08/13. The analyst maintained their Strong Buy rating on the stock.
Hiking their price target on Insmed, Huynh said that "the approval of Brinsupri comes with an 'in-line' label, so investors will now focus on launch execution."
For Q2 2025, Insmed reported:
For FY 2025, management guided:
Chairman & CEO Will Lewis commented: "Q2 2025 heralded another important milestone for patients and Insmed, with the Phase 2b PAH study of TPIP yielding topline results that surpassed our expectations.
"Insmed is now 'three for three' in terms of positive clinical trial results for our late-stage assets, and we have a line-up of additional anticipated milestones with the potential to expand our impact on patients expected over the next twelve months.
“Our teams continue to demonstrate executional excellence as we await the widely anticipated FDA approval and launch of brensocatib in bronchiectasis, advance our TPIP program in both PH-ILD and PAH, prepare for topline data from our Phase 2b BiRCh study of brensocatib in chronic rhinosinusitis without nasal polyps by the end of the year, and progress toward the read-out of our Phase 3 ENCORE study of ARIKAYCE in 1H 2026.
“Importantly, each of these events represents an opportunity to fulfill Insmed's mission to transform the lives of patients with serious diseases."
Leonid Timashev, a top 34% analyst from RBC Capital maintains INSM with a buy rating and raises their INSM price target from $120.00 to $138.00, on Aug 13, 2025.
Andrea Tan, a bottom 2% analyst from Goldman Sachs maintains INSM with a strong buy rating and raises their INSM price target from $114.00 to $142.00, on Aug 13, 2025.
Matthew Harrison, a top 25% analyst from Morgan Stanley downgrades INSM to a hold rating and raises their INSM price target from $112.00 to $126.00, on Aug 13, 2025.
You can dive deeper into what analysts are saying on the Insmed stock forecast page.
Last year, INSM revenue was $381.03M. During the past 5 year, INSM's revenue has gone up by 20.27% per year. This was slower than the Biotechnology industry average of 66.23%.
Dig into INSM's earnings and revenue performance here.
In the last year, insiders at INSM have sold more shares than they have bought.
Melvin Md Sharoky, Director of INSM, was the latest INSM insider to sell. They sold $1,295,000.00 worth of INSM shares on Aug 20, 2025.
Research more about who owns INSM stock here.
No, Insmed doesn't provide an income stream by paying out dividends.
One of the primary reasons eToro is our top-rated brokerage is because of its social trading community.
Click below to learn what other community members have to say.
There are two main order types:
Hit the Open Trade button and your broker will place your order.
If you require more help with buying stocks on eToro, click the helpful video below:
Now that you own some INSM shares, you'll want to stay up-to-date on your shares.
Add INSM to a watchlist to keep tabs on your INSM stock.
To reiterate, here are the 6 steps you need to take to buy Insmed stock right now:
If you require a brokerage account, eToro is our recommended option.
Get Started with eToro TodayIf you want to get notifications regarding your investment in Insmed, create your watchlist below.